Novartis CEO shrugs off oral PCSK9 threat amid Q2 growth
Novartis’ CEO remains unfazed by the threat of a newly approved oral PCSK9 inhibitor in Merck & Co.’s…
Merck adds to pharma’s AI push; Roche details MS drug results
This story was originally published on BioPharma Dive. To receive daily news and insights, subscribe to our free…
Roche’s DAC investment; Big Pharma’s lavish CEO bumps
This story was originally published on PharmaVoice. To receive daily news and insights, subscribe to our free daily…
UBS Raises Merck (MRK) Price Forecast as Part of Sector Preview
Merck & Co., Inc. (NYSE:MRK) is included among the 10 Healthcare Stocks with Highest Dividends. UBS Raises Merck…
Novartis, UNP, Launch Up-to-$1.8B+ Macrocyclic Peptide Partnership
Novartis will apply Unnatural Products (UNP)’s artificial intelligence (AI)-guided macrocyclic peptide platform to develop next-generation cardiovascular disease therapeutics,…